Abstract
Etanercept, a tumor necrosis factor (TNF) receptor alpha antagonist is licensed for the treatment in patients affected by polyarticular juvenile idiopathic arthritis, who do not tolerate or had an inadequate response to methotrexate. Infections related to immunosuppression by etanercept are of major concern. We report on a 17-year-old boy with enthesitis-related arthritis who developed a major infection of an urachal cyst 18 months after initiation of etanercept therapy, which required surgery. The urachus had not been symptomatic before.
Similar content being viewed by others
Abbreviations
- MTX:
-
Methotrexate
- TNF:
-
Tumor necrosis factor
- MRI:
-
Magnetic resonance imaging
References
Cilento BG Jr, Bauer SB, Retik AB, Peters CA, Atala A (1998) Urachal anomalies: defining the best diagnostic modality. Urology 52:120–122
Hamilton CD (2004) Infectious complications of treatment with biologic agents. Curr Opin Rheumatol 16:393–398
Horneff G, Schmeling H, Biedermann T, Foeldvari I, Ganser G, Girschick HJ, Hospach T, Huppertz HI, Keitzer R, Kuster RM, Michels H, Moebius D, Rogalski B, Thon A (2004) The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 63:1638–1644
Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Martin Mola E, Pavelka K, Sany J, Settas L, Wajdula J, Pedersen R, Fatenejad S, Sanda M (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363:675–681
Kunzmann S, Warmuth-Metz M, Girschick HJ (2005) Cerebral demyelination in association with TNF-inhibition therapy in a 5-year-old girl with aseptic meningitis as the first symptom of Still’s disease. Scand J Rheumatol 34:76–78
Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Whitmore J, Finck BK (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 342:763–769
Lovell DJ, Giannini EH, Reiff A, Jones OY, Schneider R, Olson JC, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Lange M, Finck BK, Burge DJ (2003) Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum 48:218–226
Luo CC, Huang CS, Wu WC, Chu SM, Chao HC (2004) An unusual presentation of an infected urachal cyst: case report and review of the literature. Eur J Pediatr 163:268–269
Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ, Ruderman EM, Horwitz DA, Arkfeld DG, Garrison L, Burge DJ, Blosch CM, Lange ML, McDonnell ND, Weinblatt ME (1999) Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 130:478–486
Phillips K, Husni ME, Karlson EW, Coblyn JS (2002) Experience with etanercept in an academic medical center: are infection rates increased? Arthritis Rheum 47:17–21
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Holl-Wieden, A., Beer, M., Marx, A. et al. Infection of an urachal cyst during etanercept therapy in juvenile idiopathic arthritis. Rheumatol Int 28, 819–822 (2008). https://doi.org/10.1007/s00296-008-0521-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-008-0521-z